A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.
Advanced Malignant Tumors
DRUG: IAP0971
Frequency of adverse events (AEs) and SAEs (Phase Ib), To investigate the safety characteristics., 3 months after end event visit|Dose limiting toxicities (DLTs) (Phase Ib), To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)., 21 days after first dose|PFS in dose expansion (Phase II), To explore the clinical effectiveness. Tumor response based on RECIST 1.1., Baseline through up to 2 years or until disease progression
Pharmacokinetic (PK) Cmax (Phase Ib), PK parameters (Cmax) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) Cmin (Phase Ib), PK parameters (Cmin) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) Tmax (Phase Ib), PK parameters (Tmax) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) AUC 0-t (Phase Ib), PK parameters (AUC 0-t) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) AUC 0-∞ (Phase Ib), PK parameters (AUC 0-∞) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) Vd (Phase Ib), PK parameters (Vd) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) t1/2 (Phase Ib), PK parameters (t1/2) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) λz (Phase Ib), PK parameters (λz) following single dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) Css,max, PK parameters (Css,max) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) Css,min, PK parameters (Css,min) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) Css,av, PK parameters (Css,av) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) AUCss, PK parameters (AUCss) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) CKss, PK parameters (CLss) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK）Vss, PK parameters (Vss) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) R, PK parameters (R) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Pharmacokinetic (PK) DF, PK parameters (DF) following multiple dose., Day1，2，3，4，6，7，11，14，21 of each subsequent cycle (each cycle is 21 days), and at the End of Treatment visit, up to about 2 years|Objective response rate (ORR) in dose escalation (Phase Ib), Tumor response based on RECIST 1.1., Baseline through up to 2 years or until disease progression|Incidence of adverse events (AEs) and SAEs (Phase Ib), To investigate the safety characteristics., 3 months after end event visit|Immunogenicity of IAH0968 (Phase Ib), The frequency of anti-drug antibodies (ADA) against IAP0971.(Phase Ib), 3 months after end event visit|ORR (Phase Ⅱ), ORR as assessed using RECIST 1.1., Baseline through up to 2 years or until disease progression|Overall survival (OS) (Phase II), OS as assessed using RECIST 1.1., Baseline through up to 2 years or until disease progression|Disease control rate (DCR) (Phase II), DCR as assessed using RECIST 1.1., Baseline through up to 2 years or until disease progression|Incidence of adverse events (AEs) and SAEs (Phase II), To investigate the safety characteristics., 3 months after end event visit|Immunogenicity of IAH0968 (Phase II), The frequency of anti-drug antibodies (ADA) against IAP0971.(Phase II), 3 months after end event visit
This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.